Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations (OPACE): A Double Blind Adaptive Design Pragmatic Phase IV Randomised Controlled Trial

NCT05772013 is registered in ClinicalTrials.gov with Dr Ian B Wilkinson as lead sponsor.

NCT NCT05772013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05772013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations (OPACE): A Double Blind Adaptive Design Pragmatic Phase IV Randomised Controlled Trial
Lead sponsor
Dr Ian B Wilkinson
Phase
Phase 4
Overall status
Recruiting
Start date
March 5, 2024
Completion date
November 30, 2028
Enrollment
1,311 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease